| 國立成功大學 |
2023 |
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
|
Tsuboi, M.;Herbst, R.S.;John, T.;Kato, T.;Majem, Majem M.;Groh�, C.;Wang, J.;Goldman, J.W.;Lu, S.;Su, W.-C.;De, Marinis F.;Shepherd, F.A.;Lee, K.H.;Le, N.T.;Dechaphunkul, A.;Kowalski, D.;Poole, L.;Bolanos, A.;Rukazenkov, Y.;Wu, Y.-L. |
| 臺大學術典藏 |
2022-06-27T06:59:40Z |
Osimertinib in resected EGFR-mutated non–small-cell lung cancer
|
Wu Y.-L.; Tsuboi M.; He J.; John T.; Grohe C.; Majem M.; Goldman J.W.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.-V.; Lu S.; Lee K.-Y.; Akewanlop C.; CHONG-JEN YU; de Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Hodge R.; Atasoy A.; Rukazenkov Y.; Herbst R.S. |
| 臺大學術典藏 |
2022-06-27T06:59:32Z |
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
|
Wu Y.-L.; Tsuboi M.; John T.; Grohe C.; Majem M.; Goldman J.W.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.-V.; Lu S.; Lee K.-Y.; Akewanlop C.; CHONG-JEN YU; De Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Hodge R.; Atasoy A.; Rukazenkov Y.; Herbst R.S. |
| 臺大學術典藏 |
2021-05-02T03:29:23Z |
Osimertinib in resected EGFR-mutated non–small-cell lung cancer
|
Wu Y.-L.;Tsuboi M.;He J.;John T.;Grohe C.;Majem M.;Goldman J.W.;Laktionov K.;Kim S.-W.;Kato T.;Vu H.-V.;Lu S.;Lee K.-Y.;Akewanlop C.;Chong-Jen Yu;De Marinis F.;Bonanno L.;Domine M.;Shepherd F.A.;Zeng L.;Hodge R.;Atasoy A.;Rukazenkov Y.;Herbst R.S.; Wu Y.-L.; Tsuboi M.; He J.; John T.; Grohe C.; Majem M.; Goldman J.W.; Laktionov K.; Kim S.-W.; Kato T.; Vu H.-V.; Lu S.; Lee K.-Y.; Akewanlop C.; CHONG-JEN YU; de Marinis F.; Bonanno L.; Domine M.; Shepherd F.A.; Zeng L.; Hodge R.; Atasoy A.; Rukazenkov Y.; Herbst R.S. |
| 臺大學術典藏 |
2020-05-26T09:27:11Z |
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
|
Fukuoka M;Wu Y.-L;Thongprasert S;Sunpaweravong P;Leong S.-S;Sriuranpong V;Chao T.-Y;Nakagawa K;Chu D.-T;Saijo N;Duffield E.L;Rukazenkov Y;Speake G;Jiang H;Armour A.A;To K.-F;Chih-Hsin Yang;Mok T.S.K.; Fukuoka M; Wu Y.-L; Thongprasert S; Sunpaweravong P; Leong S.-S; Sriuranpong V; Chao T.-Y; Nakagawa K; Chu D.-T; Saijo N; Duffield E.L; Rukazenkov Y; Speake G; Jiang H; Armour A.A; To K.-F; CHIH-HSIN YANG; Mok T.S.K. |
| 臺大學術典藏 |
2020-05-26T09:27:11Z |
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
|
Fukuoka M;Wu Y.-L;Thongprasert S;Sunpaweravong P;Leong S.-S;Sriuranpong V;Chao T.-Y;Nakagawa K;Chu D.-T;Saijo N;Duffield E.L;Rukazenkov Y;Speake G;Jiang H;Armour A.A;To K.-F;Chih-Hsin Yang;Mok T.S.K.; Fukuoka M; Wu Y.-L; Thongprasert S; Sunpaweravong P; Leong S.-S; Sriuranpong V; Chao T.-Y; Nakagawa K; Chu D.-T; Saijo N; Duffield E.L; Rukazenkov Y; Speake G; Jiang H; Armour A.A; To K.-F; CHIH-HSIN YANG; Mok T.S.K. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
|
Wu Y.-L;Fukuoka M;Mok T.S.K;Saijo N;Thongprasert S;Chih-Hsin Yang;Chu D.-T;Chih-Hsin Yang;Rukazenkov Y.; Wu Y.-L; Fukuoka M; Mok T.S.K; Saijo N; Thongprasert S; CHIH-HSIN YANG; Chu D.-T; CHIH-HSIN YANG; Rukazenkov Y. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
|
Wu Y.-L;Fukuoka M;Mok T.S.K;Saijo N;Thongprasert S;Chih-Hsin Yang;Chu D.-T;Chih-Hsin Yang;Rukazenkov Y.; Wu Y.-L; Fukuoka M; Mok T.S.K; Saijo N; Thongprasert S; CHIH-HSIN YANG; Chu D.-T; CHIH-HSIN YANG; Rukazenkov Y. |
| 臺大學術典藏 |
2020-05-26T09:26:40Z |
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
|
Fukuoka M.;Rukazenkov Y;Haddad V;Young H;Mok T.S.K;Yang J.-J;Ichinose Y;Ohe Y;Sunpaweravong P;Chewaskulyong B;Margono B;Han B;Chih-Hsin Yang;Thongprasert S;Saijo N;Wu Y.-L; Wu Y.-L; Saijo N; Thongprasert S; CHIH-HSIN YANG; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang J.-J; Mok T.S.K; Young H; Haddad V; Rukazenkov Y; Fukuoka M. |
| 臺大學術典藏 |
2020-05-26T09:26:40Z |
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
|
Fukuoka M.;Rukazenkov Y;Haddad V;Young H;Mok T.S.K;Yang J.-J;Ichinose Y;Ohe Y;Sunpaweravong P;Chewaskulyong B;Margono B;Han B;Chih-Hsin Yang;Thongprasert S;Saijo N;Wu Y.-L; Wu Y.-L; Saijo N; Thongprasert S; CHIH-HSIN YANG; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang J.-J; Mok T.S.K; Young H; Haddad V; Rukazenkov Y; Fukuoka M. |
